Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).
Elena Verzoni
No relevant relationships to disclose
Roberto Iacovelli
No relevant relationships to disclose
Mimma Rizzo
No relevant relationships to disclose
Alessandra Felici
No relevant relationships to disclose
Stefano Cascinu
No relevant relationships to disclose
Giuseppe Di Lorenzo
No relevant relationships to disclose
Linda Cerbone
No relevant relationships to disclose
Cinzia Ortega
No relevant relationships to disclose
Cristina Masini
No relevant relationships to disclose
Maria Olga Giganti
No relevant relationships to disclose
Vito Lorusso
No relevant relationships to disclose
Caterina Messina
No relevant relationships to disclose
Francesco Atzori
No relevant relationships to disclose
Fabio De Vincenzo
No relevant relationships to disclose
Cosimo Sacco
No relevant relationships to disclose
Francesco Boccardo
No relevant relationships to disclose
Francesco Valduga
No relevant relationships to disclose
Francesco Massari
No relevant relationships to disclose
Renato Tassi
No relevant relationships to disclose
Giuseppe Procopio
No relevant relationships to disclose